Drug Profile
Research programme: atherosclerosis vaccines - Abcentra
Alternative Names: CVX-210-HLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator CardioVax
- Developer Abcentra
- Class Peptide fragments; Vaccines
- Mechanism of Action Helper-inducer T-lymphocyte modulators; Natural killer T cell stimulants; Th1 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis; Cardiovascular disorders
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route) (Abcentra pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route) (Abcentra pipeline, February 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Atherosclerosis in USA